Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations

(2015) Andreas Woerner et al.   Expert Review of Clinical Immunology

Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial

(2015) Fabrizio De Benedetti et al.   Arthritis & Rheumatology

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2015) Sarah Ringold et al.   ARTHRITIS AND RHEUMATISM

Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis

(2014) Anne M Selvaag et al.   ANNALS OF THE RHEUMATIC DISEASES

Growth abnormalities in children and adolescents with juvenile idiopathic arthritis

(2014) Susanne Bechtold et al.   RHEUMATOLOGY INTERNATIONAL

Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score

(2014) Alessandro Consolaro et al.   ARTHRITIS CARE & RESEARCH

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

Disease Course, Outcome, and Predictors of Outcome in a Population-based Juvenile Chronic Arthritis Cohort Followed for 17 Years

(2013) L. Bertilsson et al.   JOURNAL OF RHEUMATOLOGY

Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis

(2013) F. McErlane et al.   RHEUMATOLOGY

Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons

(2012) Marieke H Otten et al.   ANNALS OF THE RHEUMATIC DISEASES

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

A 5-year prospective population-based study of juvenile chronic arthritis: onset, disease process, and outcome

(2012) L Bertilsson et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis

(2011) Ellen Nordal et al.   ARTHRITIS AND RHEUMATISM

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort

(2010) Kiem Oen et al.   ARTHRITIS CARE & RESEARCH

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

(2009) H. M. Albers et al.   ARTHRITIS AND RHEUMATISM

Natural History of Growth and Body Composition in Juvenile Idiopathic Arthritis

(2009) S. Bechtold et al.   HORMONE RESEARCH

Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

(2009) R. A.G. RUSSO et al.   JOURNAL OF RHEUMATOLOGY

Macrophage activation syndrome in rheumatic disease: What is the role of the antigen presenting cell?

(2008) Edward M. Behrens   AUTOIMMUNITY REVIEWS